We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326633

CAS#: 129618-40-2

Description: Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS. As with other antiretroviral drugs, HIV rapidly develops resistance if nevirapine is used alone, so recommended therapy consists of combinations of three or more antiretrovirals. Nevirapine in triple combination therapy has been shown to suppress viral load effectively when used as initial antiretroviral therapy (i.e., in antiretroviral-naive patients).

Price and Availability

Size Price Shipping out time Quantity
10mg USD 90 2 Weeks
25mg USD 120 2 Weeks
50mg USD 190 2 Weeks
100mg USD 250 2 Weeks
200mg USD 450 2 Weeks
500mg USD 950 2 Weeks
1g USD 1650 2 Weeks
2g USD 2650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-29. Prices are subject to change without notice.

Nevirapine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326633
Name: Nevirapine
CAS#: 129618-40-2
Chemical Formula: C15H14N4O
Exact Mass: 266.1168
Molecular Weight: 266.304
Elemental Analysis: C, 67.65; H, 5.30; N, 21.04; O, 6.01

Synonym: BI-RG-587; BIRG 0587; BIRG587; HSDB 7164; Nevirapine; NSC 641530; NVP; Brand name: Viramune Viramune XR.

IUPAC/Chemical Name: 11-cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one


InChi Code: InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Cornejo Castro EM, Carr DF, Jorgensen AL, Alfirevic A, Pirmohamed M. HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis. Pharmacogenet Genomics. 2015 Apr;25(4):186-98. doi: 10.1097/FPC.0000000000000124. Review. PubMed PMID: 25714001.

2: Čolić A, Alessandrini M, Pepper MS. Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. Drug Metab Rev. 2015 May;47(2):111-23. doi: 10.3109/03602532.2014.982864. Epub 2014 Nov 13. Review. PubMed PMID: 25391641.

3: Jiang HY, Zhang MN, Chen HJ, Yang Y, Deng M, Ruan B. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2014 Aug;25:130-5. doi: 10.1016/j.ijid.2014.04.020. Epub 2014 Jun 6. Review. PubMed PMID: 24911886.

4: Podzamczer D. Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine. AIDS Rev. 2013 Oct-Dec;15(4):195-203. Review. PubMed PMID: 24192600.

5: Kawalec P, Kryst J, Mikrut A, Pilc A. Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013 Oct 7;8(10):e76587. doi: 10.1371/journal.pone.0076587. eCollection 2013. Review. PubMed PMID: 24116123; PubMed Central PMCID: PMC3792044.

6: Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One. 2013 Jul 22;8(7):e68995. doi: 10.1371/journal.pone.0068995. Print 2013. Review. PubMed PMID: 23894391; PubMed Central PMCID: PMC3718822.

7: Bendle M, Bajpai S, Choudhary A, Pazare A. Prevention of perinatal HIV I transmission by protease inhibitor based triple drug antiretroviral therapy versus nevirapine as single dose at the time of delivery. J Assoc Physicians India. 2012 Dec;60:39-44. Review. PubMed PMID: 23781668.

8: Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, Hargreaves S, Mills EJ, Ford N. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013 Jun 1;27(9):1403-12. doi: 10.1097/QAD.0b013e32835f1db0. Review. PubMed PMID: 23343913.

9: Ford N, Calmy A, Andrieux-Meyer I, Hargreaves S, Mills EJ, Shubber Z. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS. 2013 Apr 24;27(7):1135-43. doi: 10.1097/QAD.0b013e32835e0752. Review. PubMed PMID: 23299174.

10: Bera E, Mia R. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. S Afr Med J. 2012 Oct 8;102(11 Pt 1):855-9. doi: 10.7196/samj.5700. Review. Erratum in: S Afr Med J. 2012 Dec;102(12):898. PubMed PMID: 23116743.

11: Bhatti L, Gladstein J. Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation. J Int Assoc Physicians AIDS Care (Chic). 2012 Nov-Dec;11(6):369-73. doi: 10.1177/1545109712456427. Epub 2012 Aug 27. Review. PubMed PMID: 22930796.

12: Coster LO, Kumar PN. Contemporary role of nevirapine in HIV treatment. AIDS Rev. 2012 Apr-Jun;14(2):132-44. Review. PubMed PMID: 22627609.

13: Lopez-Delgado JC, Mendiluce RM, Pinol TS, Fernández XP, Sanchez L, Vicente RG. Urgent liver transplantation for nevirapine-induced acute liver failure: report of a case and review of the literature. Ann Transplant. 2012 Jan-Mar;17(1):122-7. Review. PubMed PMID: 22466918.

14: Heil EL, Corbett AH. Guidelines for the use of extended-release nevirapine in HIV-infected patients. Expert Opin Pharmacother. 2011 Dec;12(17):2713-8. doi: 10.1517/14656566.2011.630391. Epub 2011 Oct 29. Review. PubMed PMID: 22035406.

15: Muret P, Piedoux S, Solas C, Quaranta S; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. [Evidence-based therapeutic drug monitoring for nevirapine]. Therapie. 2011 May-Jun;66(3):187-95. doi: 10.2515/therapie/2011030. Epub 2011 Aug 9. Review. French. PubMed PMID: 21819802.

16: Parienti JJ, Peytavin G. Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation. Expert Opin Drug Metab Toxicol. 2011 Apr;7(4):495-503. doi: 10.1517/17425255.2011.565331. Epub 2011 Mar 20. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):783. PubMed PMID: 21417819.

17: Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD004246. doi: 10.1002/14651858.CD004246.pub3. Review. PubMed PMID: 21154355.

18: Parienti JJ, Verdon R. [Nevirapine and cardiovascular risk]. Med Mal Infect. 2010 Sep;40(9):499-505. doi: 10.1016/j.medmal.2010.02.002. Review. French. PubMed PMID: 20434285.

19: Popovic M, Shenton JM, Chen J, Baban A, Tharmanathan T, Mannargudi B, Abdulla D, Uetrecht JP. Nevirapine hypersensitivity. Handb Exp Pharmacol. 2010;(196):437-51. doi: 10.1007/978-3-642-00663-0_15. Review. PubMed PMID: 20020271.

20: Kazennova EV. [Drug resistance of HIV-1 as a result of using nevirapine for chemoprophylaxis of vertical viral transmission from HIV-infected mother to infant]. Vopr Virusol. 2009 Jan-Feb;54(1):45-8. Review. Russian. PubMed PMID: 19253732.